安罗替尼联合GP方案治疗晚期非小细胞肺癌的疗效分析  

Efficacy Analysis of Anlotinib Combined with GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：石颜慧 王君伟 左一凡 武素芳 闫江涛 高立伟 SHI Yanhui;WANG Junwei;ZUO Yifan;WU Sufang;YAN Jiangtao;GAO Liwei(Oncology Department,General Hospital of Pingmei Shenma Medical Group,Pingdingshan 467000 China;Radiology Department,General Hospital of Pingmei Shenma Medical Group,Pingdingshan 467000 China)

机构地区：[1]平煤神马医疗集团总医院肿瘤科,河南平顶山467000 [2]平煤神马医疗集团总医院放射科,河南平顶山467000

出　　处：《锦州医科大学学报》2024年第6期85-89,共5页Journal of Jinzhou Medical University

基　　金：河南省医学科技攻关计划联合共建项目,项目编号:LHGJ20191258。

摘　　要：目的分析安罗替尼联合GP方案(吉西他滨+顺铂)治疗晚期非小细胞肺癌患者的疗效。方法将2020年9月至2022年9月于平煤神马医疗集团总医院诊疗的98例晚期非小细胞肺癌患者通过红黄摸球法均分为对照组和观察组。对照组应用GP方案化疗,观察组在GP方案上口服安罗替尼胶囊治疗。比较两组治疗前和治疗4个周期后的临床疗效、血清肿瘤标志物、血清学指标及随访1年的生存状况。结果观察组客观缓解率(81.63%)、疾病控制率(95.92%)比对照组(46.94%、77.55%)更高(P<0.05)。治疗4个周期后,两组癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原125(carbohydrate antigen 125,CA125)、细胞角蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,CYFRA21-1)、人非小细胞肺癌抗原(lung cancer antigen,LTA)水平均降低,观察组降低幅度更大(P<0.05)。治疗4个周期后,两组可溶性细胞间黏附分子-1(soluble intercellular adhesion molecule-1,sICAM-1)、基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)、血管内皮生长因子(vascular endothelial growth factor,VEGF)水平均降低,观察组降低幅度更大;E-钙黏素(e-cadherin,E-cad)水平均提高,观察组提高幅度更大(P<0.05)。随访1年,观察组的生存率95.92%高于对照组的79.59%(P<0.05)。结论晚期非小细胞肺癌患者在GP方案基础上加用安罗替尼能够显著提高疗效,降低肿瘤标志物水平,改善血清学指标水平,延长生存周期。Objective To analyze the efficacy of anlotinib combined with GP regimen(gemcitabine+cisplatin)in the treatment of advanced non-small cell lung cancer.Methods 98 patients with advanced non-small cell lung cancer treated from September 2020 to September 2022 in General Hospital of Pingmei Shenma Medical Gronp were divided into control group and observation group by red-yellow touch ball method.The control group was treated with GP regimen chemotherapy,and the observation group was treated with anlotinib capsules on the basis of GP regimen.The clinical efficacy,serum tumor markers,serological indicators and 1-year survival status were compared between the two groups before treatment and after 4 cycles of treatment.Results The objective remission rate(81.63%)and disease control rate(95.92%)of the observation group were higher than those of the control group(46.94%,77.55%)(P<0.05).After 4 treatment cycles,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and human non-small cell lung cancer antigen(LTA)were decreased in both groups,and the reduction was greater in the observation group(P<0.05).After 4 cycles of treatment,the levels of soluble intercellular adhesion molecule-1(sICAM-1),matrix metalloproteinase-2(MMP-2)and vascular endothelial growth factor(VEGF)were decreased in both groups,and the decrease was greater in the observation group.The levels of e-cadherin(E-cad)were all increased,and the increasing range was greater in the observation group(P<0.05).The survival rate of observation group was 95.92%higher than that of control group(P<0.05).Conclusion In advanced non-small cell lung cancer patients,the addition of anlotinib on the basis of GP regimen can significantly improve the efficacy,reduce the level of tumor markers,improve the level of serological indicators,and prolong the survival cycle.

关 键 词：安罗替尼 非小细胞肺癌 GP方案 基质金属蛋白酶-2 人非小细胞肺癌抗原 

分 类 号：R734.2[医药卫生—肿瘤]